Xiao, Le http://orcid.org/0000-0003-4323-036X
Zhao, Qian
Li, An-ning
Sun, Jushui
Wu, Bin
Wang, Lina
Zhang, Honggeng
Zhang, Ruiling
Li, Keqing
Xu, Xiaojin
Liu, Tiebang
Zhang, Wenshun
Xie, Shiping
Xu, Xiufeng
Tan, Yunlong
Zhang, Kerang
Zhang, Hongyan
Guan, Nianhong
Xian, Mingji
Uki, Motomichi
Wang, Gang
Funding for this research was provided by:
Otsuka Pharmaceutical Co., Ltd
Article History
Received: 10 March 2021
Accepted: 6 December 2021
First Online: 6 January 2022
Declarations
:
: Dr. Gang Wang disclosed receipt of research funds from the National Key Research and Development Program of China (2016YFC1307200, 2017YFC1311100), the Capital’s Funds for Health Improvement and Research (2018–1-2121), and the Demonstration research ward of Beijing Health Committee (BCRW202009). Dr. Gang Wang had received research support from Pfizer and Merck & Co., Inc. Dr. Le Xiao and An-ning Li disclosed receipt of research funds from the National Natural Science Foundation (81901372; 81801322). Dr. Motomichi Uki is an employee of Otsuka Pharmaceutical Co., Ltd. Mingji Xian is an employee of Otsuka Beijing Research Institute. The other authors declare no conflict of interest concerning this article.